Literature DB >> 1717574

A frameshift mutation at the NH2 terminus of the nucleoprotein gene does not affect generation of cytotoxic T lymphocyte epitopes.

J V Fetten1, N Roy, E Gilboa.   

Abstract

BALB/3T3 cells infected with a retroviral vector encoding the influenza virus nucleoprotein (NP) gene are efficiently lysed by CTL generated in BALB/c mice (H-2d background). Cells transduced with a mutant form of NP which contains a frameshift mutation at its NH2 terminus (NPm) do not express biochemically detectable levels of protein but nevertheless present Ag to CTL with high efficiency. Cold target inhibition studies indicate that the same CTL epitope(s) are recognized in cells harboring NP or NPm. L929 cells transduced with the NPm gene also present Ag efficiently to CTL raised in C3H mice (H-2k background). Cells engineered to express 5- to 15-fold lower levels of wild-type NP were not capable of presenting Ag to CTL, arguing against the notion that CTL are able to lyse cells expressing very low levels of Ag which might have resulted from suppression of the frameshift mutation in NPm. Implications to the mechanism of epitope generation in class I MHC-restricted immune responses are considered.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1717574

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  18 in total

Review 1.  DRiPs solidify: progress in understanding endogenous MHC class I antigen processing.

Authors:  Jonathan W Yewdell
Journal:  Trends Immunol       Date:  2011-09-29       Impact factor: 16.687

2.  RNA polymerase II inhibitors dissociate antigenic peptide generation from normal viral protein synthesis: a role for nuclear translation in defective ribosomal product synthesis?

Authors:  Brian P Dolan; Jonathan J Knowlton; Alexandre David; Jack R Bennink; Jonathan W Yewdell
Journal:  J Immunol       Date:  2010-11-03       Impact factor: 5.422

Review 3.  Exploiting non-canonical translation to identify new targets for T cell-based cancer immunotherapy.

Authors:  Céline M Laumont; Claude Perreault
Journal:  Cell Mol Life Sci       Date:  2017-08-19       Impact factor: 9.261

4.  Varied Role of Ubiquitylation in Generating MHC Class I Peptide Ligands.

Authors:  Jiajie Wei; Damien Zanker; Anthony R Di Carluccio; Margery G Smelkinson; Kazuyo Takeda; Mina O Seedhom; Devin Dersh; James S Gibbs; Ning Yang; Ajit Jadhav; Weisan Chen; Jonathan W Yewdell
Journal:  J Immunol       Date:  2017-03-31       Impact factor: 5.422

5.  Divergent evolution may link human immunodeficiency virus GP41 to human CD4.

Authors:  A Facchiano; F Facchiano; J van Renswoude
Journal:  J Mol Evol       Date:  1993-05       Impact factor: 2.395

6.  Influenza A Virus Negative Strand RNA Is Translated for CD8+ T Cell Immunosurveillance.

Authors:  Heather D Hickman; Jacqueline W Mays; James Gibbs; Ivan Kosik; Javier G Magadán; Kazuyo Takeda; Suman Das; Glennys V Reynoso; Barbara F Ngudiankama; JiaJie Wei; John P Shannon; Daniel McManus; Jonathan W Yewdell
Journal:  J Immunol       Date:  2018-07-16       Impact factor: 5.422

Review 7.  Translating DRiPs: MHC class I immunosurveillance of pathogens and tumors.

Authors:  Luis C Antón; Jonathan W Yewdell
Journal:  J Leukoc Biol       Date:  2014-02-14       Impact factor: 4.962

Review 8.  Nowhere to hide: unconventional translation yields cryptic peptides for immune surveillance.

Authors:  Shelley R Starck; Nilabh Shastri
Journal:  Immunol Rev       Date:  2016-07       Impact factor: 12.988

9.  Influence of HAART on alternative reading frame immune responses over the course of HIV-1 infection.

Authors:  Stephane Champiat; Rui André Saraiva Raposo; Nicholas J Maness; John L Lehman; Sean E Purtell; Aaron M Hasenkrug; Jacob C Miller; Hansi Dean; Wayne C Koff; Marisa Ailin Hong; Jeffrey N Martin; Steven G Deeks; Gerald E Spotts; Christopher D Pilcher; Fredrick M Hecht; Esper G Kallas; Keith E Garrison; Douglas F Nixon
Journal:  PLoS One       Date:  2012-06-29       Impact factor: 3.240

10.  Does B7-1 expression confer antigen-presenting cell capacity to tumors in vivo?

Authors:  A Y Huang; A T Bruce; D M Pardoll; H I Levitsky
Journal:  J Exp Med       Date:  1996-03-01       Impact factor: 14.307

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.